Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Co., Ltd.

https://www.daiichisankyo.com/index.html

Latest From Daiichi Sankyo Co., Ltd.

Pharma Execs Jumping Onboard Private Equity Train

More C-Suite level pharma executives are lending their domain expertise to private equity firms, which then use their skills for commercial due diligence on targets or in an operating partner role in portfolio companies once a deal is sealed. PEs are also increasingly opting for control deals, at least in India, with an aim to run the acquired firm professionally thereon.

India Commercial

Five Phase III Data Readouts To Look Out For In Q2

Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.

Clinical Trials Companies

Oncology And US Dominate Daiichi's New Mid-Term Plan

Major Japanese firm sets targets under a new mid-term plan that envisages the US oncology sector leading growth and revenues, and also casts an eye to novel assets beyond three pillar antibody-drug conjugates and new digital technologies.

Business Strategies Research and Development Strategies

Asia Deal Watch: Takeda Keeps Up Hectic Deals Pace Via Three New Alliances

Takeda pursues RNA-targeting R&D with Evotec and Anima, looks into liver disease with Genevant. Plus deals involving Kyowa Kirin/Twist, Bright Peak/Ajinimoto & Torii/Verrica.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Ambit Biosciences Corporation
    • Asubio Pharmaceuticals, Inc.
    • Daiichi Sankyo RD Novare Co., Ltd.
    • Kitasato Daiichi Sankyo K.K.
    • Im Co., Ltd., Luitpold Pharmaceuticals, Inc. (American Regent, Inc., PharmaForce, Inc.)
    • Plexxikon Inc.
    • Ranbaxy Laboratories Ltd.
    • Roxro Pharma, Inc.
    • Sankyo Pharma
    • Suntory Pharmaceutical
    • U3 Pharma AG
    • Daiichi Sankyo India Pharma Private Limited
    • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
    • Zenotech Laboratories Ltd.
    • Daiichi Sankyo Vietnam Company Limited.
UsernamePublicRestriction

Register